prostate cancer Archives - Page 58 of 63 - Sperling Prostate Center

Active Surveillance and Testosterone Replacement Therapy

The fact that an opinion has been widely held is no evidence whatever that it is not utterly absurd. – Bertrand Russell What man over the age of, say, 45 doesn’t look back—perhaps nostalgically—on the lusty days of yore? Somewhere between the ages of eighteen to thirty, men reach a sexual peak in which desire keep reading

Hormone Therapy Affects Mental Function

Androgen deprivation therapy (ADT) is a treatment for prostate cancer that has spread outside the gland. It is also called hormone therapy or chemical castration. The purpose of ADT is to reduce the production of male hormones, especially testosterone, which has the effect of temporarily halting the ability of prostate cancer cells to multiply and keep reading

Updated Focal Therapy Data From NIH

Dr. Peter Pinto is one of the most respected urologic researchers in America. He is the Head of the Prostate Cancer Section of the Urologic Oncology Branch of the Center for Cancer Research (National Cancer Institute/National Institutes of Health). That’s a very long formal title for a man who is humble, personable and good-natured. His keep reading

A Critique of Transperineal Biopsy Study On MRI/Ultrasound Fusion Guidance

I read a study on the accuracy of prostate MRI for predicting that no prostate cancer (PCa) is present. This is called the negative predictive value (NPV), and the authors make a great point in their introduction: The reliability of a negative MRI is a key clinical metric – if the MRI is reported as keep reading

Active Surveillance: Things You Might Not Have Thought About

The number of prostate cancer patients who opt for active surveillance (AS) is rising. The most important reason men go on AS is to avoid the risks that accompany whole-gland treatments. In fact, it’s so important to patients that according to a Dutch study, 30% who were not considered candidates for AS chose it anyway keep reading

MRI/Ultrasound Fusion: Not Ready for Prime Time

When an authoritative person weighs in on a topic, we sit up and take notice. Dr. Ardeshir (Art) Rastinehead is an Interventional Urologic Oncologist and he is impressively credentialed. His experience includes fellowship training at the National Cancer Institute (NIH) with. Peter A. Pinto and Bradford J. Wood, pioneers in the research and development of keep reading

Does Money Buy Life?

Everyone knows that money doesn’t buy happiness. But can it buy life? A new study out of the University of Washington Medical Center suggests that prostate cancer patients in extreme financial distress are more likely to die than those who are not. This doesn’t mean that having money can buy life, but hardship is a keep reading

MRI/Ultrasound Fusion: Not Ready for Prime Time

When an authoritative person weighs in on a topic, we sit up and take notice. Dr. Ardeshir (Art) Rastinehead is an Interventional Urologic Oncologist and he is impressively credentialed. His experience includes fellowship training at the National Cancer Institute (NIH) with. Peter A. Pinto and Bradford J. Wood, pioneers in the research and development of keep reading

A Call for High Level Academic Science to Validate New Technologies

I never cease to be amazed at the amount of publication that comes from various individuals and teams at the University College London. On top of their clinical work with patients, and conducting clinical trials, I am impressed with their commitment and energy level when it comes to setting fingers to keyboard and writing articles keep reading

Risk of Prostate Cancer, Cholesterol, and Other Health Factors

For decades, researchers have been looking for a link between prostate cancer and other health factors such as obesity, smoking, or diet. They don’t have to look very hard. There is a huge amount of evidence that links prostate cancer risk with these and other conditions—making a powerful case for making healthy choices. But what keep reading

Tag: prostate cancer